Cargando…

COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches

Vaccine anaphylaxis is rare; however, severe allergic reactions after administration of a coronavirus disease 2019 (COVID-19) vaccines have been reported. Excipients in the vaccine may play a role in severe allergic reactions post-vaccination. Various mechanisms, including IgE-mediated pathways, dir...

Descripción completa

Detalles Bibliográficos
Autor principal: Laisuan, Wannada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974674/
https://www.ncbi.nlm.nih.gov/pubmed/35387045
http://dx.doi.org/10.3389/falgy.2021.801322
_version_ 1784680247766024192
author Laisuan, Wannada
author_facet Laisuan, Wannada
author_sort Laisuan, Wannada
collection PubMed
description Vaccine anaphylaxis is rare; however, severe allergic reactions after administration of a coronavirus disease 2019 (COVID-19) vaccines have been reported. Excipients in the vaccine may play a role in severe allergic reactions post-vaccination. Various mechanisms, including IgE-mediated pathways, direct mass cell stimulation via the Mas-related G protein-coupled receptor-X2, and complement pathway activation, have been proposed to cause the anaphylaxis. Skin testing, using the basophil activation test, has been used to clarify the mechanism of the anaphylaxis and provide safety information for the next injection. Here, we review the current evidence and suggested approaches for patients who experienced an immediate severe allergic reaction to the first dose of a COVID-19 vaccine.
format Online
Article
Text
id pubmed-8974674
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89746742022-04-05 COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches Laisuan, Wannada Front Allergy Allergy Vaccine anaphylaxis is rare; however, severe allergic reactions after administration of a coronavirus disease 2019 (COVID-19) vaccines have been reported. Excipients in the vaccine may play a role in severe allergic reactions post-vaccination. Various mechanisms, including IgE-mediated pathways, direct mass cell stimulation via the Mas-related G protein-coupled receptor-X2, and complement pathway activation, have been proposed to cause the anaphylaxis. Skin testing, using the basophil activation test, has been used to clarify the mechanism of the anaphylaxis and provide safety information for the next injection. Here, we review the current evidence and suggested approaches for patients who experienced an immediate severe allergic reaction to the first dose of a COVID-19 vaccine. Frontiers Media S.A. 2021-12-23 /pmc/articles/PMC8974674/ /pubmed/35387045 http://dx.doi.org/10.3389/falgy.2021.801322 Text en Copyright © 2021 Laisuan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Allergy
Laisuan, Wannada
COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches
title COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches
title_full COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches
title_fullStr COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches
title_full_unstemmed COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches
title_short COVID-19 Vaccine Anaphylaxis: Current Evidence and Future Approaches
title_sort covid-19 vaccine anaphylaxis: current evidence and future approaches
topic Allergy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974674/
https://www.ncbi.nlm.nih.gov/pubmed/35387045
http://dx.doi.org/10.3389/falgy.2021.801322
work_keys_str_mv AT laisuanwannada covid19vaccineanaphylaxiscurrentevidenceandfutureapproaches